Sign Out
Malignant Pleural Mesothelioma: In combination with cisplatin, for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Non-small Cell Lung Cancer: In combination with cisplatin for first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see Pharmacology: Pharmacodynamics under Actions).
Indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see Pharmacology: Pharmacodynamics under Actions).
Indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see Pharmacology: Pharmacodynamics under Actions).
In combination with pembrolizumab and platinum chemotherapy for the first line treatment of patients with metastatic nonsquamous non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations.
Continue with Google